Depression and acitretin: a true association or a class labeling?

Area of Science:

• Dermatology
• Psychiatry
• Pharmacology

Background:

• Systemic retinoids, particularly acitretin used for psoriasis, are under scrutiny for potential links to affective disorders.
• This concern is heightened due to acitretin's chemical similarity to isotretinoin, which has numerous anecdotal reports of depression and suicidal ideation.
• An FDA warning on acitretin packaging regarding depression and suicide has amplified patient safety concerns.

Purpose of the Study:

• To conduct a comprehensive review of existing literature on the association between acitretin and affective disorders.
• To evaluate the scientific evidence supporting or refuting a causal link between acitretin use and mood disturbances.

Main Methods:

• Literature review of published case reports and clinical studies.
• Analysis of reported adverse events associated with acitretin and isotretinoin.
• Examination of the timeline and basis for FDA labeling regarding affective disorders.

Main Results:

• Only two cases of affective disorders linked to acitretin have been reported globally over 12 years of use.
• No clinical studies have definitively proven a causal relationship between isotretinoin and depression or suicidal ideation.
• No systematic clinical studies specifically investigating acitretin's association with affective disorders have been conducted.

Conclusions:

• The reported cases involving acitretin are minimal, suggesting a weak or non-existent association with affective disorders.
• The FDA precaution for acitretin appears to be based on class labeling rather than robust scientific evidence.
• Further systematic research is needed to definitively establish or refute the link between acitretin and affective disorders.